Edward Chow1, Amanda Hird2, Galina Velikova3, Colin Johnson4, Linda Dewolf5, Andrea Bezjak6, Jackson Wu7, Jesmin Shafiq8, Orhan Sezer9, Dimitrios Kardamakis10, Yvette van der Linden11, Brigette Ma12, Monica Castro13, Palmira Foro Arnalot14, Sam Ahmedzai15, Mark Clemons6, Peter Hoskin16, Albert Yee2, Michael Brundage17, Andrew Bottomley5. 1. Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, Ontario, Canada M4N 3M5. Electronic address: edward.chow@sunnybrook.ca. 2. Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, Ontario, Canada M4N 3M5. 3. Cancer Research UK Clinical Centre, University of Leeds, St James's University Hospital, Leeds, UK. 4. University Surgical Unit, Southampton General Hospital, UK. 5. European Organization for Research and Treatment of Cancer, Brussel, Belgium. 6. Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada. 7. Tom Baker Cancer Centre, University of Calgary, Calgary, Alberta, Canada. 8. Liverpool Hospital, Liverpool, New South Wales, Australia. 9. Charité, Universitaetsmedizin Berlin, Germany. 10. University of Patras Medical School, Patras, Greece. 11. Radiotherapeutic Institute Friesland, Leeuwarden, The Netherlands. 12. Prince of Wales Hospital, Chinese University of Hong Kong, Shatin, China. 13. Instituto de Oncologia Angel H. Roffo, Universidad de Buenos Aires, Argentina. 14. Hospital de l'Esperança, Sant Josep de la Muntanya, Barcelona, Spain. 15. St Lukes Hospice, Little Common Lane, Sheffield, UK. 16. Mount Vernon Hospital, Northwood, Middlesex, UK. 17. Kingston Regional Cancer Centre, Kingston, Ontario, Canada.
Abstract
AIM: The aim of this study was to develop a bone metastases module to supplement the European Organisation for Research and Treatment of Cancer Core Questionnaire (EORTC QLQ-C30) or the EORTC QLQ-C15-PAL for patients with bone metastases. METHODS: Phases 1-2 of module development were conducted in Canada, Australia and Germany according to EORTC QOL group guidelines. Phase 3 was conducted in nine countries in seven languages. RESULTS: Sixty-one health-related quality of life (HRQOL) issues were generated from health care professionals (n=152) and patients (n=413). This resulted in a 22-item provisional module. Further testing in 170 patients from nine countries resulted in the EORTC QLQ-BM22 module, containing 22 items, conceptualised into both symptom scales, with five painful sites and three pain characteristics, and also functional scales, with eight functional interference and six psychosocial aspects. CONCLUSION: This study provides a provisional comprehensive HRQOL measurement tool for future trials, which will continue to undergo further validation.
AIM: The aim of this study was to develop a bone metastases module to supplement the European Organisation for Research and Treatment of Cancer Core Questionnaire (EORTC QLQ-C30) or the EORTC QLQ-C15-PAL for patients with bone metastases. METHODS: Phases 1-2 of module development were conducted in Canada, Australia and Germany according to EORTC QOL group guidelines. Phase 3 was conducted in nine countries in seven languages. RESULTS: Sixty-one health-related quality of life (HRQOL) issues were generated from health care professionals (n=152) and patients (n=413). This resulted in a 22-item provisional module. Further testing in 170 patients from nine countries resulted in the EORTC QLQ-BM22 module, containing 22 items, conceptualised into both symptom scales, with five painful sites and three pain characteristics, and also functional scales, with eight functional interference and six psychosocial aspects. CONCLUSION: This study provides a provisional comprehensive HRQOL measurement tool for future trials, which will continue to undergo further validation.
Authors: Janneke van Roij; Heidi Fransen; Lonneke van de Poll-Franse; Myrte Zijlstra; Natasja Raijmakers Journal: Qual Life Res Date: 2018-02-10 Impact factor: 4.147
Authors: Srinivas Raman; Keyue Ding; Edward Chow; Ralph M Meyer; Abdenour Nabid; Pierre Chabot; Genevieve Coulombe; Shahida Ahmed; Joda Kuk; A Rashid Dar; Aamer Mahmud; Alysa Fairchild; Carolyn F Wilson; Jackson S Y Wu; Kristopher Dennis; Carlo DeAngelis; Rebecca K S Wong; Liting Zhu; Michael Brundage Journal: Qual Life Res Date: 2016-05-02 Impact factor: 4.147
Authors: Rachel McDonald; Keyue Ding; Edward Chow; Ralph M Meyer; Abdenour Nabid; Pierre Chabot; Genevieve Coulombe; Shahida Ahmed; Joda Kuk; Rashid Dar; Aamer Mahmud; Alysa Fairchild; Carolyn F Wilson; Jackson S Y Wu; Kristopher Dennis; Carlo DeAngelis; Rebecca K S Wong; Liting Zhu; Michael Brundage Journal: Support Care Cancer Date: 2016-07-27 Impact factor: 3.603
Authors: Mirosława Püsküllüoğlu; Krzysztof A Tomaszewski; Andrew Bottomley; Lori Holden; Iwona M Tomaszewska; Roman Głowacki; Krzysztof Bereza; Edward B Golec; Edward Chow; Krzysztof Krzemieniecki Journal: Qual Life Res Date: 2013-08-03 Impact factor: 4.147